

ARTICLE

HEALTHCARE ABOVE POLITICS:
US - CHINA TRACK II DIALOGUE

October 2023

ABSTRACT: Geographic, linguistic, resource and even political constraints impede effective collaboration among US and Chinese healthcare professionals. This is an unfortunate situation for global healthcare, given the clinical and scientific leadership in each country. Recognizing this, senior representatives from both sides have identified foundational elements needed to improve healthcare conditions in China and the US. This article identifies a realistic path towards executing those elements.

TABLE OF CONTENTS

BACKGROUND 2

REAL-WORLD EVIDENCE AND CIRCLES 2

RELEVANCE OF CIRCLES TO TRACK II HEALTHCARE DIALOGUE 3

CONCLUSION 3

FOR FURTHER INFORMATION 4

FOOTNOTES 5

BACKGROUND

This past summer, the [National Committee on US - China Relations](#) and the [National School of Development](#) convened “Track II” discussions on healthcare.¹ Senior Chinese and US representatives from industry, academia and clinical practices met face-to-face for the first time in four years.

The “[Consensus Agreement](#)” resulting from those discussions highlighted the following goals relevant to healthcare issues pertaining to both countries:

- Meaningful and sustained collaboration among Chinese and US healthcare professionals (“HCP’s”) on specific areas of mutual interest.
- Joint design and execution of traditional clinical trials, supported by real-world evidence.

- Use of modern electronic platforms for healthcare data capture, aggregation, analysis, and clinical decision-making.
- Developing standards of care for broader population samples, including the underserved.
- Integration of primary care protocols with those of specialty, social and community practices.
- Improving opportunities for, and methods of communications among, HCPs of both countries.
- Use of modern digital technology to improve patient understanding, engagement, and compliance.

The following sections propose a cost-effective yet clinical-grade approach to achieving these objectives.

REAL-WORLD EVIDENCE AND CIRCLES

Real-world evidence (“RWE”) underlies many of the recommendations of the Consensus Agreement. RWE is essential to standards of care, better clinical decisions, value-based medicine, product improvement, patient engagement, and reimbursement.² It is relevant to any pathology, indication, medical product, or clinical/scientific interest.

[RegenMed](#) is a product-agnostic company led by internationally recognized physicians and scientists. The Company’s sole focus is generating demonstrable and sustained clinical and scientific value from RWE on behalf of its Clients.

RegenMed’s Circles integrate the technical platforms³ and processes⁴ which drive RWE value opportunities in a minimally

burdensome manner. Circles are used around the world by providers, medical

societies, industry, and other healthcare constituencies.⁵

RELEVANCE OF CIRCLES TO TRACK II HEALTHCARE DIALOGUE

Translating broad Track II objectives into achievable reality is challenging. But modern technology and processes dedicated to supporting cross-border HCP collaboration allow concrete progress in an economical and minimally burdensome manner.

Objective: Real-World Studies

Circles are used for registries and various forms of trials and studies⁶, both on a stand-alone basis and to support more narrowly defined trials.

Objective: Genuine HCP Collaboration

Circles' user-experience focuses on sustained collaboration. They inherently support multi-lingual/cultural work across institutional and national borders.

Objective: Standards of Care For Underserved Populations

The Circles platform is low-cost,

accessible 24/7 from any device by patients and clinicians, and easy to use. Its UX emphasizes patient engagement, compliance and comprehension of medical conditions and proposed treatment paths.

Objective: Modern Digital Technology

Circles are based on patented technical platforms.⁷ These enable the efficient and economical collection, aggregation and analysis of real-world healthcare data, and the generation of clinical and scientific value from those data.

Objective: Improve Amount and Quality Of Communications

Circle Reports, Circle Hours⁸, [Circle Academies](#), [Join-A-Circle](#), [Publication](#) and similar functionality support meaningful, secure and sustained communications among Circle Members on any clinical/scientific topic of interest.

CONCLUSION

The potential for world-wide healthcare advances achievable through meaningful collaboration among US and Chinese

clinicians and scientists is enormous. This is the basic premise of the Track Healthcare II Dialogue between the two countries.

Realizing that potential is ultimately up to day-to-day interactions among those clinicians and scientists. Circles are a cost-

effective and “shovel-ready” solution to support that interaction.

FOR FURTHER INFORMATION

[US - China Track II Healthcare Dialogue](#)

[RgnMed.com/Circles/General](#)

[Join/Start A Circle](#)

[KnowledgeBase](#)

[LinkedIn](#)

[Latest](#)

[Contact Us](#)

FOOTNOTES

- ¹ Track II diplomacy or "backchannel diplomacy" is the practice of "non-governmental, informal and unofficial contacts and activities between private citizens or groups of individuals, sometimes called "non-state actors". Wikipedia.
- ² See also [Registries for Evaluating Patient Outcomes: A User's Guide: 4th Edition](#), AHRQ, U.S. Department of Health and Human Services.
- ³ The patented clinician-facing [inCytes™](#) and patient-facing [Benchmarc™](#) technologies.
- ⁴ Patient enrollment, post-procedure long-term outcomes capture, report generation, publication, ongoing collaboration support, publication, industry funding, IRB support and similar administrative elements can be handled by RegenMed.
- ⁵ Circles use cases are further described on the company's [Latest](#) and [LinkedIn](#) pages.
- ⁶ Pragmatic, observational, quality improvement, regulatory, post-market surveillance, "n of 1", investigator-initiated and other forms of studies and trials.
- ⁷ U.S. patent number 11720567, *Method and System For Processing Large Amounts of Real-World Evidence*. RegenMed is developing a family of patents and other intellectual property relating to healthcare RWE. This includes generative AI.
- ⁸ Livestreamed and recorded video conferences among Circle Members to discuss observations, correlations, best-practices, and other matters.